Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-β in mouse endometrium.

Eritja N, Felip I, Dosil MA, Vigezzi L, Mirantes C, Yeramian A, Navaridas R, Santacana M, Llobet-Navas D, Yoshimura A, Nomura M, Encinas M, Matias-Guiu X, Dolcet X.

Cell Death Differ. 2017 Aug;24(8):1443-1458. doi: 10.1038/cdd.2017.73. Epub 2017 May 19.

PMID:
28524854
2.

Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.

Dosil MA, Mirantes C, Eritja N, Felip I, Navaridas R, Gatius S, Santacana M, Colàs E, Moiola C, Schoenenberger JA, Encinas M, Garí E, Matias-Guiu X, Dolcet X.

J Pathol. 2017 Jun;242(2):152-164. doi: 10.1002/path.4896. Epub 2017 Apr 28.

PMID:
28349562
3.

Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.

Eritja N, Chen BJ, Rodríguez-Barrueco R, Santacana M, Gatius S, Vidal A, Martí MD, Ponce J, Bergadà L, Yeramian A, Encinas M, Ribera J, Reventós J, Boyd J, Villanueva A, Matias-Guiu X, Dolcet X, Llobet-Navàs D.

Autophagy. 2017 Mar 4;13(3):608-624. doi: 10.1080/15548627.2016.1271512. Epub 2017 Jan 5.

4.

Endometrial Carcinoma: Specific Targeted Pathways.

Eritja N, Yeramian A, Chen BJ, Llobet-Navas D, Ortega E, Colas E, Abal M, Dolcet X, Reventos J, Matias-Guiu X.

Adv Exp Med Biol. 2017;943:149-207. Review.

PMID:
27910068
5.

Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.

Mirantes C, Dosil MA, Eritja N, Felip I, Gatius S, Santacana M, Matias-Guiu X, Dolcet X.

Eur J Cancer. 2016 Aug;63:74-87. doi: 10.1016/j.ejca.2016.04.019. Epub 2016 Jun 9.

PMID:
27288872
6.

Biological Effects of Temsirolimus on the mTOR Pathway in Endometrial Carcinoma: A Pharmacodynamic Phase II Study.

Santacana M, Coronado P, Matias-Guiu X, Romero I, Casado A, Gil-Moreno A, Dosil MA, Mota A, Moreno-Bueno G, Dolcet X, Llombart-Cussac A, Poveda A.

Int J Gynecol Cancer. 2016 Jun 2. [Epub ahead of print]

PMID:
27258723
7.

Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin.

Fusté NP, Fernández-Hernández R, Cemeli T, Mirantes C, Pedraza N, Rafel M, Torres-Rosell J, Colomina N, Ferrezuelo F, Dolcet X, Garí E.

Nat Commun. 2016 May 16;7:11581. doi: 10.1038/ncomms11581.

8.

Characterization of cytoplasmic cyclin D1 as a marker of invasiveness in cancer.

Fusté NP, Castelblanco E, Felip I, Santacana M, Fernández-Hernández R, Gatius S, Pedraza N, Pallarés J, Cemeli T, Valls J, Tarres M, Ferrezuelo F, Dolcet X, Matias-Guiu X, Garí E.

Oncotarget. 2016 May 10;7(19):26979-91. doi: 10.18632/oncotarget.8876.

9.

2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.

Yeramian A, Vea A, Benítez S, Ribera J, Domingo M, Santacana M, Martinez M, Maiques O, Valls J, Dolcet X, Vilella R, Cabiscol E, Matias-Guiu X, Marti RM.

Pigment Cell Melanoma Res. 2016 May;29(3):352-71. doi: 10.1111/pcmr.12472.

PMID:
26988132
10.

Oral intake of genetically engineered high-carotenoid corn ameliorates hepatomegaly and hepatic steatosis in PTEN haploinsufficient mice.

Eritja N, Arjó G, Santacana M, Gatius S, Ramírez-Núñez O, Arcal L, Serrano JCE, Pamplona R, Dolcet X, Piñol C, Christou P, Matias-Guiu X, Portero-Otin M.

Biochim Biophys Acta. 2016 Apr;1862(4):526-535. doi: 10.1016/j.bbadis.2016.01.018. Epub 2016 Jan 26.

11.

Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma but not myeloid malignancies.

Mirantes C, Dosil MA, Hills D, Yang J, Eritja N, Santacana M, Gatius S, Vilardell F, Medvinsky A, Matias-Guiu X, Dolcet X.

Blood. 2016 Apr 14;127(15):1907-11. doi: 10.1182/blood-2015-09-669036. Epub 2016 Jan 14.

12.

Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.

Yeramian A, García V, Bergadà L, Domingo M, Santacana M, Valls J, Martinez-Alonso M, Carceller JA, Cussac AL, Dolcet X, Matias-Guiu X.

Mol Imaging Biol. 2016 Aug;18(4):545-56. doi: 10.1007/s11307-015-0907-8.

PMID:
26604096
13.

Impaired Vitamin D Signaling in Endothelial Cell Leads to an Enhanced Leukocyte-Endothelium Interplay: Implications for Atherosclerosis Development.

Bozic M, Álvarez Á, de Pablo C, Sanchez-Niño MD, Ortiz A, Dolcet X, Encinas M, Fernandez E, Valdivielso JM.

PLoS One. 2015 Aug 31;10(8):e0136863. doi: 10.1371/journal.pone.0136863. eCollection 2015.

14.

Modeling glands with PTEN deficient cells and microscopic methods for assessing PTEN loss: endometrial cancer as a model.

Eritja N, Santacana M, Maiques O, Gonzalez-Tallada X, Dolcet X, Matias-Guiu X.

Methods. 2015 May;77-78:31-40. doi: 10.1016/j.ymeth.2014.11.001. Epub 2014 Nov 18. Review.

PMID:
25461816
15.

FISH analysis of PTEN in endometrial carcinoma. Comparison with SNP arrays and MLPA.

Maiques O, Cuevas D, García Dios DA, Coenegrachts L, Santacana M, Velasco A, Romero M, Sónia G, Lambrechts D, Dolcet X, Amant F, Matias-Guiu X.

Histopathology. 2014 Sep;65(3):371-88.

16.

A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.

Santacana M, Maiques O, Valls J, Gatius S, Abó AI, López-García MÁ, Mota A, Reventós J, Moreno-Bueno G, Palacios J, Bartosch C, Dolcet X, Matias-Guiu X.

Hum Pathol. 2014 Dec;45(12):2394-403. doi: 10.1016/j.humpath.2014.06.031. Epub 2014 Aug 23.

PMID:
25282036
17.

Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.

Alonso-Alconada L, Muinelo-Romay L, Madissoo K, Diaz-Lopez A, Krakstad C, Trovik J, Wik E, Hapangama D, Coenegrachts L, Cano A, Gil-Moreno A, Chiva L, Cueva J, Vieito M, Ortega E, Mariscal J, Colas E, Castellvi J, Cusido M, Dolcet X, Nijman HW, Bosse T, Green JA, Romano A, Reventos J, Lopez-Lopez R, Salvesen HB, Amant F, Matias-Guiu X, Moreno-Bueno G, Abal M; ENITEC Consortium.

Mol Cancer. 2014 Sep 27;13:223. doi: 10.1186/1476-4598-13-223.

18.

ETV5 transcription program links BDNF and promotion of EMT at invasive front of endometrial carcinomas.

Alonso-Alconada L, Eritja N, Muinelo-Romay L, Barbazan J, Lopez-Lopez R, Matias-Guiu X, Gil-Moreno A, Dolcet X, Abal M.

Carcinogenesis. 2014 Dec;35(12):2679-86. doi: 10.1093/carcin/bgu198. Epub 2014 Sep 18.

PMID:
25233929
19.

Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer.

Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, Monge M, Cueva J, Oliva E, Soslow RA, Lopez MA, Palacios J, Prat J, Valls J, Krakstad C, Salvesen H, Gil-Moreno A, Lopez-Lopez R, Dolcet X, Moreno-Bueno G, Reventos J, Matias-Guiu X, Abal M.

Int J Cancer. 2015 Apr 15;136(8):1863-73. doi: 10.1002/ijc.29213. Epub 2014 Sep 29.

20.

Role of local bioactivation of vitamin D by CYP27A1 and CYP2R1 in the control of cell growth in normal endometrium and endometrial carcinoma.

Bergadà L, Pallares J, Maria Vittoria A, Cardus A, Santacana M, Valls J, Cao G, Fernàndez E, Dolcet X, Dusso AS, Matias-Guiu X.

Lab Invest. 2014 Jun;94(6):608-22. doi: 10.1038/labinvest.2014.57. Epub 2014 Apr 14.

21.

Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.

Bergadà L, Yeramian A, Sorolla A, Matias-Guiu X, Dolcet X.

PLoS One. 2014 Mar 20;9(3):e92764. doi: 10.1371/journal.pone.0092764. eCollection 2014.

22.

Optimal protocol for PTEN immunostaining; role of analytical and preanalytical variables in PTEN staining in normal and neoplastic endometrial, breast, and prostatic tissues.

Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, García Dios DA, Amant F, Pedersen HC, Dolcet X, Matias-Guiu X.

Hum Pathol. 2014 Mar;45(3):522-32. doi: 10.1016/j.humpath.2013.10.018. Epub 2013 Nov 7.

23.

Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.

Eritja N, Domingo M, Dosil MA, Mirantes C, Santacana M, Valls J, Llombart-Cussac A, Matias-Guiu X, Dolcet X.

Mol Cancer Ther. 2014 Apr;13(4):776-87. doi: 10.1158/1535-7163.MCT-13-0794. Epub 2014 Jan 21.

24.

Epithelial-to-mesenchymal transition and stem cells in endometrial cancer.

Mirantes C, Espinosa I, Ferrer I, Dolcet X, Prat J, Matias-Guiu X.

Hum Pathol. 2013 Oct;44(10):1973-81. doi: 10.1016/j.humpath.2013.04.009. Epub 2013 Jul 8. Review.

PMID:
23845467
25.

Three-dimensional epithelial cultures: a tool to model cancer development and progression.

Eritja N, Dolcet X, Matias-Guiu X.

Histol Histopathol. 2013 Oct;28(10):1245-56. doi: 10.14670/HH-28.1245. Epub 2013 May 30. Review.

PMID:
23719713
26.

Long-term estradiol exposure is a direct mitogen for insulin/EGF-primed endometrial cells and drives PTEN loss-induced hyperplasic growth.

Eritja N, Mirantes C, Llobet D, Yeramian A, Bergadà L, Dosil MA, Domingo M, Matias-Guiu X, Dolcet X.

Am J Pathol. 2013 Jul;183(1):277-87. doi: 10.1016/j.ajpath.2013.03.008. Epub 2013 May 10.

PMID:
23669345
27.

Combination of Vorinostat and caspase-8 inhibition exhibits high anti-tumoral activity on endometrial cancer cells.

Bergadà L, Sorolla A, Yeramian A, Eritja N, Mirantes C, Matias-Guiu X, Dolcet X.

Mol Oncol. 2013 Aug;7(4):763-75. doi: 10.1016/j.molonc.2013.03.003. Epub 2013 Mar 28.

28.

An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.

Mirantes C, Eritja N, Dosil MA, Santacana M, Pallares J, Gatius S, Bergadà L, Maiques O, Matias-Guiu X, Dolcet X.

Dis Model Mech. 2013 May;6(3):710-20. doi: 10.1242/dmm.011445. Epub 2013 Feb 8.

29.

The EMT signaling pathways in endometrial carcinoma.

Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martínez E, Llauradó M, Rigau M, Olivan M, Garcia M, Cabrera S, Gil-Moreno A, Xercavins J, Castellvi J, Garcia A, Ramon y Cajal S, Moreno-Bueno G, Dolcet X, Alameda F, Palacios J, Prat J, Doll A, Matias-Guiu X, Abal M, Reventos J.

Clin Transl Oncol. 2012 Oct;14(10):715-20. doi: 10.1007/s12094-012-0866-3. Epub 2012 Aug 22. Review.

PMID:
22911547
30.

Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells.

Sorolla A, Yeramian A, Valls J, Dolcet X, Bergadà L, Llombart-Cussac A, Martí RM, Matias-Guiu X.

Mol Oncol. 2012 Oct;6(5):530-41. doi: 10.1016/j.molonc.2012.06.006. Epub 2012 Jul 7.

31.

Endometrial carcinoma: molecular alterations involved in tumor development and progression.

Yeramian A, Moreno-Bueno G, Dolcet X, Catasus L, Abal M, Colas E, Reventos J, Palacios J, Prat J, Matias-Guiu X.

Oncogene. 2013 Jan 24;32(4):403-13. doi: 10.1038/onc.2012.76. Epub 2012 Mar 19. Review.

PMID:
22430211
32.

ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a crucial role for TNFα and IL1α in lumen formation and maintenance.

Eritja N, Mirantes C, Llobet D, Masip G, Matias-Guiu X, Dolcet X.

J Cell Sci. 2012 Apr 15;125(Pt 8):1929-44. doi: 10.1242/jcs.095067. Epub 2012 Feb 10.

33.

Immunohistochemical features of post-radiation vaginal recurrences of endometrioid carcinomas of the endometrium: role for proteins involved in resistance to apoptosis and hypoxia.

Santacana M, Yeramian A, Velasco A, Bergada L, Gatius S, García V, Azueta A, Palacios J, Dolcet X, Oliva E, Matias-Guiu X.

Histopathology. 2012 Feb;60(3):460-71. doi: 10.1111/j.1365-2559.2011.04106.x.

PMID:
22276609
34.

Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma.

Montserrat N, Mozos A, Llobet D, Dolcet X, Pons C, de Herreros AG, Matias-Guiu X, Prat J.

Hum Pathol. 2012 May;43(5):632-43. doi: 10.1016/j.humpath.2011.06.021. Epub 2011 Sep 21.

PMID:
21940036
35.

FGFR2 alterations in endometrial carcinoma.

Gatius S, Velasco A, Azueta A, Santacana M, Pallares J, Valls J, Dolcet X, Prat J, Matias-Guiu X.

Mod Pathol. 2011 Nov;24(11):1500-10. doi: 10.1038/modpathol.2011.110. Epub 2011 Jul 1.

36.

Stem cells in human endometrium and endometrial carcinoma.

Cervelló I, Mirantes C, Santamaria X, Dolcet X, Matias-Guiu X, Simón C.

Int J Gynecol Pathol. 2011 Jul;30(4):317-27. doi: 10.1097/PGP.0b013e3182102754. Review.

PMID:
21623195
37.

Nuclear factor-κB2/p100 promotes endometrial carcinoma cell survival under hypoxia in a HIF-1α independent manner.

Yeramian A, Santacana M, Sorolla A, Llobet D, Encinas M, Velasco A, Bahi N, Eritja N, Domingo M, Oliva E, Dolcet X, Matias-Guiu X.

Lab Invest. 2011 Jun;91(6):859-71. doi: 10.1038/labinvest.2011.58. Epub 2011 May 2.

38.

The canonical nuclear factor-κB pathway regulates cell survival in a developmental model of spinal cord motoneurons.

Mincheva S, Garcera A, Gou-Fabregas M, Encinas M, Dolcet X, Soler RM.

J Neurosci. 2011 Apr 27;31(17):6493-503. doi: 10.1523/JNEUROSCI.0206-11.2011.

39.

ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.

Llauradó M, Abal M, Castellví J, Cabrera S, Gil-Moreno A, Pérez-Benavente A, Colás E, Doll A, Dolcet X, Matias-Guiu X, Vazquez-Levin M, Reventós J, Ruiz A.

Int J Cancer. 2012 Apr 1;130(7):1532-43. doi: 10.1002/ijc.26148. Epub 2011 Aug 12.

40.

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM.

Int J Cancer. 2012 Feb 15;130(4):967-78. doi: 10.1002/ijc.26096. Epub 2011 Jun 18.

41.

KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels.

Llobet D, Eritja N, Domingo M, Bergada L, Mirantes C, Santacana M, Pallares J, Macià A, Yeramian A, Encinas M, Moreno-Bueno G, Palacios J, Lewis RE, Matias-Guiu X, Dolcet X.

Am J Pathol. 2011 Apr;178(4):1529-43. doi: 10.1016/j.ajpath.2010.12.041.

42.

Cyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility.

Fernández RM, Ruiz-Miró M, Dolcet X, Aldea M, Garí E.

Oncogene. 2011 Apr 21;30(16):1936-46. doi: 10.1038/onc.2010.577. Epub 2011 Jan 17.

PMID:
21242975
43.

Promoter hypermethylation and expression of sprouty 2 in endometrial carcinoma.

Velasco A, Pallares J, Santacana M, Gatius S, Fernandez M, Domingo M, Valls J, Yeramian A, Encinas M, Dolcet X, Matias-Guiu X.

Hum Pathol. 2011 Feb;42(2):185-93. doi: 10.1016/j.humpath.2010.08.001. Epub 2010 Nov 26.

PMID:
21111454
44.

A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis.

Eritja N, Llobet D, Domingo M, Santacana M, Yeramian A, Matias-Guiu X, Dolcet X.

Am J Pathol. 2010 Jun;176(6):2722-31. doi: 10.2353/ajpath.2010.090974. Epub 2010 Apr 15.

45.

Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.

Martinez-Alonso M, Llecha N, Mayorga ME, Sorolla A, Dolcet X, Sanmartin V, Abal L, Casanova JM, Baradad M, Yeramian A, Egido R, Puig S, Vilella R, Matias-Guiu X, Marti RM.

J Int Med Res. 2009 Nov-Dec;37(6):1813-22.

PMID:
20146879
46.

The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.

Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X.

Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.

PMID:
20071162
47.

DcR1 expression in endometrial carcinomas.

Tarragona J, Llecha N, Santacana M, Lopez S, Gatius S, Llobet D, Dolcet X, Palomar-Asenjo V, Gonzalez-Tallada FJ, Matias-Guiu X.

Virchows Arch. 2010 Jan;456(1):39-44. doi: 10.1007/s00428-009-0855-2. Epub 2009 Nov 20.

PMID:
19936781
48.

A review of the applications of tissue microarray technology in understanding the molecular features of endometrial carcinoma.

Pallares J, Santacana M, Puente S, Lopez S, Yeramian A, Eritja N, Sorolla A, Llobet D, Dolcet X, Matias-Guiu X.

Anal Quant Cytol Histol. 2009 Aug;31(4):217-26. Review.

PMID:
19736869
49.

Subtractive proteomic approach to the endometrial carcinoma invasion front.

Monge M, Doll A, Colas E, Gil-Moreno A, Castellvi J, Garcia A, Colome N, Perez-Benavente A, Pedrola N, Lopez-Lopez R, Dolcet X, Ramon y Cajal S, Xercavins J, Matias-Guiu X, Canals F, Reventos J, Abal M.

J Proteome Res. 2009 Oct;8(10):4676-84. doi: 10.1021/pr900390t.

PMID:
19691290
50.

Loss of Sprouty1 rescues renal agenesis caused by Ret mutation.

Rozen EJ, Schmidt H, Dolcet X, Basson MA, Jain S, Encinas M.

J Am Soc Nephrol. 2009 Feb;20(2):255-9. doi: 10.1681/ASN.2008030267. Epub 2008 Dec 3.

Supplemental Content

Loading ...
Support Center